| Literature DB >> 35107821 |
Ryan D Kilpatrick1,2, Olga Sánchez-Soliño3, Negar Niki Alami3, Christopher Johnson3, Yixin Fang3, Lani R Wegrzyn3, Whitney S Krueger3, Yizhou Ye3, Nancy Dreyer4, Gregory C Gray5,6,7.
Abstract
INTRODUCTION: EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) is an observational, epidemiological study with a 9-month longitudinal follow-up of nonhospitalized persons aged 18 years or older currently living or employed in Lake County, IL. We describe the study design and report baseline characteristics of the study participants, including the proportion of participants with acute or previous SARS-CoV-2 infection at enrollment.Entities:
Keywords: COVID-19; Community-based research; Epidemiology; SARS-CoV-2
Year: 2022 PMID: 35107821 PMCID: PMC8808268 DOI: 10.1007/s40121-022-00593-0
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Fig. 1Study design and illustration of questionnaire administration and specimen collection. aSerology testing for quantitative IgG will be done from banked samples after adequate test is available. bQuestionnaires about health experience related to COVID-19 and social behaviors would be completed at the time of testing or every 2 weeks depending on the item to accommodate recall and HRQoL survey will be available online for completion soon after PCR and serology testing has been communicated to the participant (regardless of the test result—positive or negative) allowing for data collection approximately within 2 weeks after time of testing (i.e., at 0.5, 3.5, 6.5, and 9.5 months). Questionnaire dynamic will be based on current symptoms related to COVID-19. COVID-19 coronavirus disease 2019, HRQoL health-related quality of life, IgG immunoglobulin G, mos months, qRT-PCR quantitative reverse transcription polymerase chain reaction
Participant disposition
| Characteristic | All participants ( |
|---|---|
| State of residencea, | |
| Illinois | 992 (98.4) |
| Indiana | 16 (1.6) |
| Age at baseline (years)b | |
| Mean ± SD | 51.4 ± 13.8 |
| Age group (years), | |
| 18–29 years | 78 (7.7) |
| 30–39 years | 147 (14.6) |
| 40–49 years | 173 (17.2) |
| 50–64 years | 451 (44.7) |
| 65–74 years | 140 (13.9) |
| 75–84 years | 15 (1.5) |
| 85+ years | 4 (0.4) |
| Gender, | |
| Female | 713 (70.7) |
| Male | 293 (29.1) |
| Other | 2 (0.2) |
| Race, | |
| White | 924 (91.7) |
| Asian | 40 (4.0) |
| Other | 28 (2.8) |
| Black or African American | 10 (1.0) |
| American Indian or Alaska Native | 4 (0.4) |
| Native Hawaiian or Other Pacific Islander | 2 (0.2) |
| Ethnic origin, | |
| Not Hispanic or Latino | 954 (94.6) |
| Hispanic or Latino | 53 (5.3) |
| Prefer not to say | 1 (< 0.1) |
| BMI (kg/m2) at baselinec | |
| Mean ± SD | 28.4 ± 6.2 |
| Vaccination against COVID-19, | |
| Yes | 7 (0.7) |
| No | 968 (96.0) |
| I don't know | 33 (3.3) |
| Participating in another COVID-19 study, | 11 (1.1) |
| Smoking status, | |
| Never smoked | 703 (69.7) |
| Past smoker | 267 (26.5) |
| Current smoker | 38 (3.8) |
| Level of exposure risk to SARS-CoV-2 in their occupation, | |
| Low risk | 421 (41.8) |
| Medium–low risk | 248 (24.6) |
| Medium–high risk | 225 (22.3) |
| High risk | 114 (11.3) |
| Currently employed or in school | 743 (73.7) |
| Participants with acute or previous SARS-CoV-2 infection at baseline | |
| Overall | |
| Tested positive as part of the study | 56 (5.6) |
| Positive qualitative RT-PCR test | 20 (2.0) |
| Positive IgG test | 45 (4.5) |
| Symptomatic | |
| Tested positive as part of the study | 24 (26.1) |
| Positive qualitative RT-PCR test | 14 (15.2) |
| Positive IgG test | 17 (18.5) |
| Asymptomatic | |
| Tested positive as part of the study | 32 (3.5) |
| Positive qualitative RT-PCR test | 6 (0.7) |
| Positive IgG test | 28 (3.1) |
BMI body mass index, IgG immunoglobulin G, RT-PCR reverse transcriptase polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SD standard deviation
aNo participants enrolled from Wisconsin
bAge at baseline = (2020 − year of birth)
cBMI = (weight (kg)/height (m)2)
Number and proportion of participants with acute SARS-CoV-2 infection and evidence of previous infection at baseline
| Acute (RT-PCR) or previous (IgG-positive) infection, | Acute infection, | Previous infection, | |
|---|---|---|---|
| Level of risk in occupation | |||
| Low risk ( | 21 (5.0, [3.11–7.52]) | 7 (1.7, [0.67–3.40]) | 15 (3.6, [2.01–5.81]) |
Medium–low risk ( OR (vs low risk) | 10 (4.0, [1.95–7.29]) 0.80 (0.37–1.73) | 3 (1.2, [0.25–3.49]) 0.72 (0.19–2.83) | 9 (3.63, [1.67–6.78]) 1.02 (0.44–2.37) |
Medium–high risk ( OR (vs low risk) | 14 (6.2, [3.44–10.22]) 1.26 (0.63–2.54) | 6 (2.7, [0.99–5.71]) 1.62 (0.54–4.88) | 12 (5.3, [2.79–9.13]) 1.53 (0.70–3.32) |
High risk ( OR (vs low risk) | 11 (9.7, [4.92–16.61]) 2.03 (0.95–4.35) | 4 (3.5, [0.96–8.74]) 2.15 (0.62–7.48) | 9 (7.9, [3.67–14.46]) 2.32 (0.99–5.45) |
| Age group | |||
| 18–29 years ( | 7 (9.0, [3.69–17.62]) | 3 (3.9, [0.80–10.83]) | 6 (7.7, [2.88–16.00]) |
30–39 years ( OR (vs 18–29 years) | 9 (6.1, [2.84–11.30]) 0.66 (0.24–1.85) | 1 (0.7, [0.02–3.73]) 0.17 (0.02–1.67) | 8 (5.4, [2.38–10.44]) 0.69 (0.23–2.07) |
40–49 years ( OR (vs 18–29 years) | 10 (5.8, [2.81–10.37]) 0.62 (0.23–1.70) | 5 (2.9, [0.95–6.62]) 0.74 (0.17–3.19) | 7 (4.1, [1.64–8.16]) 0.51 (0.16–1.56) |
50–64 years ( OR (vs 18–29 years) | 21 (4.7, [2.91–7.03]) 0.50 (0.20–1.21) | 9 (2.0, [0.92–3.75]) 0.51 (0.14–1.92) | 16 (3.6, [2.04–5.70]) 0.44 (0.17–1.17) |
65+ years ( OR (vs 18–29 years) | 9 (5.7, [2.62–10.47]) 0.61 (0.22–1.70) | 2 (1.3, [0.15–4.47]) 0.32 (0.05–1.95) | 8 (5.0, [2.20–9.67]) 0.64 (0.21–1.90) |
| Gender | |||
| Female ( | 37 (5.2, [3.68–7.08]) | 14 (2.0, [1.08–3.27]) | 29 (4.1, [2.74–5.79]) |
Male ( OR (vs female) | 19 (6.5, [3.95–9.94]) 1.27 (0.72–2.24) | 6 (2.1, [0.76–4.40]) 1.04 (0.40–2.74) | 16 (5.5, [3.15–8.72]) 1.36 (0.73–2.55) |
| Other ( | 0 | 0 | 0 |
| Prefer not to answer ( | 0 | 0 | 0 |
| Race | |||
White ( OR (all other races vs White race) | 43 (4.5, [3.39–6.22]) 3.75 (1.93–7.30) | 15 (1.6, [0.91–2.66]) 3.84 (1.36–10.83) | 34 (3.7, [2.56–5.10]) 3.95 (1.92–8.11) |
| American Indian or Alaska Native ( | 0 ([0.00–60.24]) | 0 ([0.00–60.24]) | 0 [0.00–60.24]) |
| Asian ( | 6 (15.0, [5.71–29.84]) | 0 ([0.00–8.81]) | 6 (15.0, [5.71–29.84]) |
| Black or African American ( | 0 ([0.00–30.85]) | 0 ([0.00–30.85]) | 0 ([0.00–30.85]) |
| Other ( | 7 (29.17, [12.62–51.20]) | 5 (20.83, [7.13–42.15]) | 5 (20.83, [7.13–42.15]) |
| Prefer not to say ( | 0 ([0.00–60.24]) | 0 ([0.00–60.24]) | 0 ([0.00–60.24]) |
| BMI category | |||
| Normal ( | 22 (6.7, [4.24–9.95]) | 4 (1.2, [0.33–3.08]) | 20 (6.1, [3.75–9.23]) |
Overweight ( OR (vs normal) | 13 (3.9, [2.07–6.51]) 0.56 (0.28–1.13) | 5 (1.5, [0.48–3.43]) 1.22 (0.33–4.60) | 12 (3.6, [1.85–6.14]) 0.57 (0.27–1.19) |
Obese ( OR (vs normal) | 21 (6.1, [3.84–9.23]) 0.91 (0.49–1.69) | 11 (3.22, [1.62–5.68]) 2.70 (0.85–8.57) | 13 (3.8, [2.04–6.41]) 0.61 (0.30–1.25) |
| Any comorbidity | |||
| No ( | 41 (5.7, [4.12–7.66]) | 15 (2.1, [1.17–3.42]) | 32 (4.5, [3.06–6.23]) |
Yes ( OR (yes vs no) | 15 (5.2, [2.93–8.42]) 0.91 (0.49–1.66) | 5 (1.7, [0.56–3.99]) 0.83 (0.30–2.30) | 13 (4.5, [2.42–7.57]) 1.01 (0.52–1.96) |
| Symptomatic | |||
| No ( | 32 (3.5, [2.40–4.90]) | 6 (0.7, [0.24–1.42]) | 28 (3.1, [2.04–4.39]) |
Yes ( OR (yes vs no) | 24 (26.1, [17.48–36.29]) 9.75 (5.44–17.48) | 14 (15.2, [8.58–24.21]) 27.22 (10.18–72.82) | 17 (18.5, [11.15–27.93]) 7.19 (3.76–13.73) |
BMI body mass index, CI confidence interval, IgG immunoglobulin G, RT-PCR reverse transcriptase polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
Data are n (%) [95% CI]
|
|
| Current understanding of COVID-19 epidemiology, transmission dynamics, and clinical and demographic characteristics of individuals with SARS-CoV-2 is continually evolving. |
| Real-world community-based studies are important for understanding population-level drivers of risk and transmission dynamics of the pandemic, and informing future public health policy decision-making. |
| EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) study is a prospective, longitudinal, community-based study design assessing the proportion of study participants in Lake County, IL with acute or previous SARS-CoV-2 infection overall and in relation to demographic, occupational, clinical, and behavioral characteristics at baseline. |
|
|
| We report on the unique study design of this community-based study and baseline assessment of participants working or residing in Lake County, IL. |
| In this cohort, serologic and RT-PCR assessments showed that 5.6% of study participants had evidence for acute or previous SARS-CoV-2 infection and nonadherence to social distancing measures and traveling domestically since December 1, 2019 were identified as factors associated with SARS-CoV-2 infection. |